This trial is a randomized, blind, similar vaccine controlled, single center, non-inferiority design phase III clinical trial, with a study population of 10 to 60 years old, conducted in two stages.Phase 1 and Phase 2
Age range
10 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Antibody positive conversion rate - Immunogenicity endpoint
Timeframe: up to 14 days after the first/full dose of vaccination
Geometric mean concentration - Immunogenicity endpoint
Timeframe: 14 days after the first/full dose of vaccination
Incidence of Adverse Events [Safety and Tolerability]
Timeframe: within 30 minutes after each dose of vaccination
Incidence of Adverse Events [Safety and Tolerability]
Timeframe: within 0-7 days after each dose of vaccination
Incidence of Adverse Events [Safety and Tolerability]
Timeframe: within 30 days after the first dose of vaccination to the full course of vaccination
Incidence of Adverse Events [Safety and Tolerability]
Timeframe: within 6 months after the first dose administration and the entire vaccination process